

**Clinical Trials Summary for out of hours
Important Reference**

Acronym study title	<p>MK 3475-U03</p> <p>Sub-study 03A: Phase 1b/2 Umbrella Study of Combination Therapies in participants with advanced ccRCC who have not received prior systemic treatment for advanced disease</p> <p>Sub-study 03B: Phase 1b/2 Umbrella Study of Combination Therapies in participants with advanced ccRCC who have experienced disease progression or after having received systemic treatment for advanced disease</p>
Study Details	A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03) 03A & 03B Sub-studies
Principal Investigator PI Sub PI's	<p>PI – Dr Natalie Charnley Sub Investigator – Dr Omi Parikh</p>
Research Nurse Team	<p>Research Nurse - Davide Garau CTSO – Zainab Chauhan</p>
Drug therapy	<p><u>Sub-study 03A</u> ARM A1 – MK-1308A and Lenvatinib ARM A2 - MK-4280A and Lenvatinib ARM A4 - Pembrolizumab and Lenvatinib and Belzutifan</p> <p><u>Sub-study 03B</u> ARM B1 – MK-1308A ARM B2 – MK-4280A ARM B3 - Pembrolizumab and MK-4830 ARM B4 – Pembrolizumab and Belzutifan ARM B5 – Belzutifan and Lenvatinib</p>
In the event that a patient calls this hotline for advise	<p>Standard advise for Thyrosine Kinase Inhibitors. Please contact on-call registrar if patient on novel treatments.</p>

--	--